In addition, in a phase I study of the MCL1 inhibitor AMG-176 against relapsed or refractory multiple myeloma, treatment-emergent adverse events of grade 3 or higher occurred in 62% of patients, the most common being neutropenia, anemia, and hypertension [36]. This evidence concerns the gene MCL1 and AL amyloidosis.